Medway, MA, United States of America

Renee Moore

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Inventor Renee Moore

Introduction

Renee Moore is a notable inventor based in Medway, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. Her work focuses on creating innovative solutions for medical challenges, particularly in cancer treatment.

Latest Patents

Renee Moore holds a patent for anti-LAP antibody variants. This patent includes recombinant humanized, chimeric, and human anti-LAP antibodies or antigen binding fragments that possess therapeutically beneficial properties. These antibodies specifically bind to LAP-TGFβ1 on cells, while avoiding binding to LAP-TGFβ1 in the extracellular matrix. The patent also outlines various compositions that include these antibodies and their applications in therapeutic and diagnostic settings, particularly in cancer treatment.

Career Highlights

Throughout her career, Renee has worked with prominent companies in the biotechnology sector. She has been associated with Tilos Therapeutics, Inc. and Merck Sharp & Dohme Corporation, where she has contributed her expertise in antibody development and therapeutic applications.

Collaborations

Renee has collaborated with several professionals in her field, including notable coworkers such as Randall Burton and Jessie M English. These collaborations have further enhanced her research and development efforts in creating innovative therapeutic solutions.

Conclusion

Renee Moore's contributions to the field of biotechnology through her innovative patents and collaborations highlight her role as a significant inventor. Her work continues to impact the development of therapeutic applications, particularly in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…